Leap Therapeutics Inc. (LPTX)
Leap Therapeutics Statistics
Share Statistics
Leap Therapeutics has 41.26M shares outstanding. The number of shares has increased by 7.82% in one year.
Shares Outstanding | 41.26M |
Shares Change (YoY) | 7.82% |
Shares Change (QoQ) | 7.67% |
Owned by Institutions (%) | 33% |
Shares Floating | 30.76M |
Failed to Deliver (FTD) Shares | 21.87K |
FTD / Avg. Volume | 0.83% |
Short Selling Information
The latest short interest is 1.01M, so 2.63% of the outstanding shares have been sold short.
Short Interest | 1.01M |
Short % of Shares Out | 2.63% |
Short % of Float | 3.53% |
Short Ratio (days to cover) | 2.68 |
Valuation Ratios
The PE ratio is -1.6 and the forward PE ratio is -0.51. Leap Therapeutics's PEG ratio is 0.03.
PE Ratio | -1.6 |
Forward PE | -0.51 |
PS Ratio | 0 |
Forward PS | 0.4 |
PB Ratio | 3.09 |
P/FCF Ratio | -1.79 |
PEG Ratio | 0.03 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Leap Therapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.41, with a Debt / Equity ratio of 0.01.
Current Ratio | 3.41 |
Quick Ratio | 3.41 |
Debt / Equity | 0.01 |
Debt / EBITDA | 0 |
Debt / FCF | 0 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $0 |
Profits Per Employee | $-1.3M |
Employee Count | 52 |
Asset Turnover | 0 |
Inventory Turnover | n/a |
Taxes
Income Tax | -585K |
Effective Tax Rate | 0.87% |
Stock Price Statistics
The stock price has increased by -87.65% in the last 52 weeks. The beta is 0.21, so Leap Therapeutics's price volatility has been higher than the market average.
Beta | 0.21 |
52-Week Price Change | -87.65% |
50-Day Moving Average | 0.56 |
200-Day Moving Average | 2.16 |
Relative Strength Index (RSI) | 31.13 |
Average Volume (20 Days) | 2.65M |
Income Statement
Revenue | n/a |
Gross Profit | 0 |
Operating Income | -70.06M |
Net Income | -67.79M |
EBITDA | -70.06M |
EBIT | n/a |
Earnings Per Share (EPS) | -1.81 |
Balance Sheet
The company has 47.25M in cash and 266K in debt, giving a net cash position of 46.98M.
Cash & Cash Equivalents | 47.25M |
Total Debt | 266K |
Net Cash | 46.98M |
Retained Earnings | -467.37M |
Total Assets | 49.12M |
Working Capital | 33.96M |
Cash Flow
In the last 12 months, operating cash flow was -60.3M and capital expenditures 0, giving a free cash flow of -60.3M.
Operating Cash Flow | -60.3M |
Capital Expenditures | 0 |
Free Cash Flow | -60.3M |
FCF Per Share | -1.61 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
LPTX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for LPTX is $8, which is 2480.6% higher than the current price. The consensus rating is "Hold".
Price Target | $8 |
Price Target Difference | 2480.6% |
Analyst Consensus | Hold |
Analyst Count | 2 |
Stock Splits
The last stock split was on Jun 21, 2023. It was a backward split with a ratio of 1:10.
Last Split Date | Jun 21, 2023 |
Split Type | backward |
Split Ratio | 1:10 |
Scores
Altman Z-Score | -16.7 |
Piotroski F-Score | 1 |